![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and_Q320.jpg)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review | International Journal of Gynecologic Cancer Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/early/2023/08/29/ijgc-2023-004487/F2.large.jpg)
Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review | International Journal of Gynecologic Cancer
![Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram](https://www.researchgate.net/publication/233746224/figure/fig2/AS:601587995136000@1520441163001/Progression-free-survival-and-overall-survival-curves-for-all-patients-with-different.png)
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
![Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram](https://www.researchgate.net/publication/306551418/figure/fig3/AS:567236567855104@1512251144196/Progression-free-survival-PFS-A-and-overall-survival-OS-B-based-on-disease-free.png)
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/RCT-of-Letrozole-in-Post-menopausal-breast-cancer.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086418309353-gr1.jpg)
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2407-14-18/MediaObjects/12885_2013_Article_4261_Fig1_HTML.jpg)
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F4.large.jpg)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-01042-y/MediaObjects/41375_2020_1042_Fig2_HTML.png)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure2-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)